VALN - FDA Approves World's First Mosquito-Borne Chikungunya Vaccine | Benzinga
The FDA approved Valneva SE's (NASDAQ: VALN) Chikungunya single-dose vaccine in individuals aged 18 and above.
The company plans to start selling the vaccine, dubbed Ixchiq, in the U.S. early next year.
Ixchiq was approved using the Accelerated Approval pathway
"Continued approval for this indication is contingent upon verification of clinical benefit in confirmatory studies," Valneva said.
With this U.S. approval, Ixchiq becomes the world's first licensed chikungunya vaccine and the third ...